180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Update

Posted by Eileen French on Mar 19th, 2025

180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 33,500 shares, a growth of 29.3% from the February 13th total of 25,900 shares. Currently, 2.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 410,200 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 180 Life Sciences in a report on Friday, March 7th.

Check Out Our Latest Report on 180 Life Sciences

180 Life Sciences Stock Up 0.0 %

Shares of ATNF opened at $1.07 on Wednesday. 180 Life Sciences has a 12-month low of $0.98 and a 12-month high of $17.75. The business has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $2.03.

Hedge Funds Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Anson Funds Management LP bought a new position in 180 Life Sciences Corp. (NASDAQ:ATNF – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned approximately 7.08% of 180 Life Sciences as of its most recent SEC filing. 4.07% of the stock is owned by institutional investors and hedge funds.

180 Life Sciences Company Profile

(Get Free Report)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.